NIH Council of Councils Members Named
First Official Meeting to be Held March 31-April 1, 2008
The National Institutes of Health (NIH) today announces the appointments
to the NIH Council of Councils. The Council is made up of 27 members
selected from the NIH Institute and Center (IC) advisory councils
and advisory committees to the NIH Office of the Director. The
Council will advise the NIH Director on cutting-edge trans-NIH
priorities and matters related to the policies and activities of
the Division of Program Coordination, Planning, and Strategic Initiatives,
established by the NIH Reform Act 2006, and the Office of Portfolio
Analysis and Strategic Initiatives (OPASI). The Council also will
act as an external advisory panel to the IC Directors during the
concept approval stage of the review process for trans-NIH initiatives.
"My charge to the Council is to be bold and define experiments
that engage the community that NIH can do and fund reasonably," said
NIH Director Elias A. Zerhouni, M.D. "The Council should foster
incubation of new ideas and build resources as needed, all driven
by analysis of the science."
The Council of Councils and the Common Fund to support trans-NIH
initiatives were authorized by the NIH Reform Act of 2006 signed
into law by the President in January 2007. This act was the first
omnibus reauthorization of NIH in 14 years. A
major element of the Reform Act of 2006 was the new authority it
gave to the NIH Director to improve program coordination, assemble
accurate data, implement strategic plans based on IC-determined
priorities, ensure resources are properly allocated, and further
maximize investigator-initiated research.
More information on the Council of Council's role and the NIH
Reform Act of 2006 can be found at http://www.nih.gov/about/reauthorization/index.htm.
The Council's first official meeting will be held March 31-April
1, 2008, on the NIH campus, Bethesda, Md. The meeting is open to
the public; an agenda and registration information are available
on the Council's website (http://opasi.nih.gov/council).
The following are serving terms on the Council:
Ronald L. Arenson, M.D., University of California,
San Francisco, liaison to the National Institute of Biomedical
Imaging and Bioengineering
Enriqueta C. Bond, Ph.D., Burroughs-Wellcome Fund, Research Triangle
Park, N.C., liaison to the National Institute of Child Health and
Human Development
Donna Bates Boucher, Bates Group, Inc., Denver, Colo., liaison
to the National Institute on Deafness and Other Communication Disorders
Richard Chabran, M.L.S., California Community Technology Policy
Group, Los Angeles, Calif., liaison to the National Library of
Medicine
Coleen K. Cunningham, M.D., Duke University Medical Center, Durham,
N.C., liaison to the Office of AIDS Research
Robert M. Dickler, Association of American Medical Colleges, Washington,
D.C., liaison to the NIH Clinical Center
Cecile A. Feldman, D.M.D., M.B.A., University of Medicine and Dentistry
of New Jersey, Newark, N.J., liaison to the National Institute
of Dental and Craniofacial Research
Edwin Flores, Ph.D., J.D., Chalker Flores, LLP, Dallas, Texas,
liaison to the National Institute of General Medical Sciences
Joseph H. Graziano, Ph.D., Mailman School of Public Health and
College of Physicians and Surgeons, Columbia University, New York,
N.Y., liaison to the National Institute of Environmental Health
Sciences
Bevra H. Hahn, M.D., David Geffen School of Medicine, University
of California - Los Angeles, liaison to the National Institute
of Arthritis and Musculoskeletal and Skin Diseases
Mary J.C. Hendrix, Ph.D., Feinberg School of Medicine, Northwestern
University, Chicago, liaison to the National Cancer Institute
Dilip V. Jeste, M.D., Sam and Rose Stein Institute for Research
on Aging, University of California -San Diego and Veterans Administration
Medical Center, San Diego, liaison to the National Institute of
Mental Health
Lenworth N. Johnson, M.D., University of Missouri - Columbia, liaison
to the National Eye Institute
Warren A. Jones, M.D., F.A.A.F.P., Mississippi Institute for Improvement
of Geographic Minority Health, University of Mississippi Medical
Center, Jackson, liaison to the National Center on Minority Health
and Health Disparities
Arthur M. Kleinman, M.D., Harvard University Medical School, Cambridge,
Mass., liaison to the John E. Fogarty International Center for
Advanced Study in the Health Sciences
Joseph Loscalzo, M.D., Ph.D., Brigham and Women's Hospital and
Harvard Medical School, Boston, liaison to the National Heart,
Lung, and Blood Institute
Marjorie K. Mau, M.D., John A. Burns School of Medicine, University
of Hawaii at Manoa, Honolulu, liaison to the Council of Public
Representatives
Juanita L. Merchant, M.D., Ph.D., University of Michigan, Ann Arbor,
liaison to the National Institute of Diabetes and Digestive and
Kidney Diseases
Sandra Millon-Underwood, Ph.D., R.N., University of Wisconsin -
Milwaukee, liaison to the National Institute of Nursing Research
Daria Mochly-Rosen, Ph.D., Stanford University School of Medicine,
Calif., liaison to the Center for Scientific Review
Sergio R. Ojeda, D.V.M., Oregon National Primate Research Center,
Oregon Health and Science University School of Medicine, Beaverton,
Ore., liaison to the National Institute of Child Health and Human
Development
Orien Reid, M.S.W., Alzheimer's Disease International, Consumer
Connection, Laverock, Pa., liaison to the National Institute on
Aging
Martin Rosenberg, Ph.D., Promega Corporation, Madison, WI, liaison
to the National Institute of Allergy and Infectious Diseases
Richard A. Rudick, M.D., The Mellen Center, Cleveland Clinic Foundation,
Ohio, liaison to the National Center for Research Resources
Harold T. Shapiro, Ph.D., The Woodrow Wilson School of Public and
International Affairs, Princeton University, N.J., liaison to the
National Human Genome Research Institute
Phyllis M. Wise, Ph.D., University of Washington, Seattle, liaison
to the Office of Research on Women's Health
Marina E. Wolf, Ph.D., Rosalind Franklin University of Medicine
and Science, North Chicago, liaison to the National Institute on
Drug Abuse
Alan M. Krensky, M.D., Director, OPASI, is Chairperson of the Council.
The Council's Executive Secretary is Elizabeth L. Wilder, P.D.,
Acting Associate Director of OPASI.
The following additional persons will represent three NIH ICs at
the March 31-April 1, 2008, meeting:
Joan E. Fox, Ph.D., Cleveland Clinic and Lerner College of Medicine,
Western Reserve University, Cleveland, Ohio, liaison to the National
Center for Complementary and Alternative Medicine
Victor M. Hesselbrock, Ph.D., University of Connecticut
Health Center, School of Medicine, Farmington, Conn., liaison to
the National Institute on Alcohol Abuse and Alcoholism
Gary L. Westbrook, M.D., The Vollum Institute and Oregon Health
and Science University, Portland, liaison to the National Institute
of Neurological Disorders and Stroke
A roster with further information about the members is posted
on the Council's website (http://opasi.nih.gov/council/roster.asp).
The Office of Portfolio Analysis and Strategic Initiatives (OPASI),
within the Office of the NIH Director, provides the NIH with the
methods and information necessary to manage large and complex scientific
portfolios, identifies important areas of emerging scientific opportunities
or rising public health challenges, and assists in the acceleration
of investments in these areas focusing on those involving multiple
Institutes and Centers. For more information about OPASI, visit http://opasi.nih.gov.
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and
Centers and is a component of the U.S. Department of Health and
Human Services. It is the primary federal agency for conducting
and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both
common and rare diseases. For more information about NIH and
its programs, visit www.nih.gov.
|